financetom
Business
financetom
/
Business
/
Neo Performance Materials Reports Improved and Higher Than Expected Q3 Earnings and Revs; Raises FY 2025 Adjusted EBITDA Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Neo Performance Materials Reports Improved and Higher Than Expected Q3 Earnings and Revs; Raises FY 2025 Adjusted EBITDA Guidance
Nov 14, 2025 6:52 AM

09:24 AM EST, 11/14/2025 (MT Newswires) -- Neo Performance Materials ( NOPMF ) on Friday reported improved and higher than expected third quarter adjusted earnings and revenues, while it raised its 2025 adjusted EBITDA outlook.

The company's third-quarter adjusted net income was reported at US$8.5 million, or $0.20 earnings per share basic and $0.19 earnings per share diluted, compared to $1.1 million or $0.03 earnings per share basic and diluted in the corresponding year-ago quarter. The consensus estimates compiled by FactSet for non-GAAP EPS was $0.13 per share.

Third-quarter revenue was US$122.2 million, compared to $111.3 million in the year-ago quarter. The consensus estimates compiled by FactSet for revenue was $109.5 million.

Neo delivered $19.2 million and $55.3 million in Adjusted EBITDA for the three and nine months ended September 30, 2025, marking a 1.9% decrease and 26.5% increase, respectively, from the same periods last year. The company raised its 2025 adjusted EBITDA outlook to $67-$71 million, up from $64-$68 million as announced in August.

"Our third-quarter results highlight Neo's ability to deliver strong operational performance while advancing our strategy to grow our industry-leading permanent magnet business," said Rahim Suleman, Neo's President and Chief Executive Officer. He noted that in delivering $19 million in Q3 Adjusted EBITDA, this brings year to date total to $55 million, a 27% increase compared to the same period last year, prompting the raised guidance.

"So far this year," Suleman added, "we have achieved several major milestones, advancing the new heavy rare earth separation line in Europe, securing traction-motor magnet contracts with European Tier 1 customers, extending our partnership with Bosch, and, in September, celebrating the grand opening of our new industrial scale sintered magnet plant in Europe. With production beginning in mid-2026, the facility will have productive capacity of 2,000 tonnes annually in its first phase, with plans to expand to 5,000 tonnes. As we continue executing our long-term strategy, Neo is poised to become the critical enabler of diversified and localized permanent-magnet supply chains for the West."

NEO noted a quarterly dividend of C$0.10 per common share was declared on Nov. 11, 2025, unchanged from the last quarter, for shareholders of record on Dec. 19, 2025, with a payment date of Dec. 29, 2025.

Its shares fell 7.65% on the TSX yesterday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Jefferies Financial Hires JPMorgan's Melly as APAC FIG Deals Head
Market Chatter: Jefferies Financial Hires JPMorgan's Melly as APAC FIG Deals Head
Aug 18, 2025
04:27 AM EDT, 08/18/2025 (MT Newswires) -- Jefferies Financial Group ( JEF ) is bringing on Michael Melly from JPMorgan (JPM) to head its financial institutions group investment banking franchise for Asia-Pacific, Bloomberg News reported Sunday, citing people familiar with the matter. Melly is expected to start as soon as later this year and will oversee deals involving banks, insurers,...
Ascentage Pharma Receives US, EU Approvals for Study of Potential Myelodysplastic Syndrome Treatment
Ascentage Pharma Receives US, EU Approvals for Study of Potential Myelodysplastic Syndrome Treatment
Aug 18, 2025
04:22 AM EDT, 08/18/2025 (MT Newswires) -- Ascentage Pharma ( AAPG ) said Sunday it has received clearance from the US Food and Drug Administration and the European Medicines Agency to conduct a phase 3 study of its drug lisaftoclax in combination with azacitidine for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome. The study is now enrolling...
Bragg Gaming Reports Cybersecurity Incident
Bragg Gaming Reports Cybersecurity Incident
Aug 18, 2025
04:39 AM EDT, 08/18/2025 (MT Newswires) -- Bragg Gaming Group ( BRAG ) said Sunday that it found out about a cybersecurity breach Saturday and has taken steps to mitigate any potential impact. Preliminary investigations suggest the data breach was limited to the company's internal computer environment, with no indication that any personal information was impacted, Bragg said. The incident...
Varonis Systems Insider Sold Shares Worth $2,464,933, According to a Recent SEC Filing
Varonis Systems Insider Sold Shares Worth $2,464,933, According to a Recent SEC Filing
Aug 18, 2025
04:16 AM EDT, 08/18/2025 (MT Newswires) -- Guy Melamed, Chief Financial Officer and Chief Operating Officer, on August 13, 2025, sold 42,705 shares in Varonis Systems ( VRNS ) for $2,464,933. Following the Form 4 filing with the SEC, Melamed has control over a total of 427,897 common shares of the company, with 427,897 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1361113/000162828025040580/xslF345X05/wk-form4_1755295468.xml...
Copyright 2023-2026 - www.financetom.com All Rights Reserved